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We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing 
cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real-world clinical setting. 
Analyzing data from 1,001 patients recruited to the UK-PSC research cohort, we evaluated clinical variables for 
their association with 2-year and 10-year outcome through Cox-proportional hazards and C-statistic analyses. We 
generated risk scores for short-term and long-term outcome prediction, validating their use in two independent co-
horts totaling 451 patients. Thirty-six percent of the derivation cohort were transplanted or died over a cumulative 
follow-up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis 
was predictive of 10-year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant-free survival 63 versus 
108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed 
two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of ex-
trahepatic biliary disease, and variceal hemorrhage, which predicted 2-year and 10-year outcomes with good dis-
crimination (C statistic = 0.81 and 0.80, respectively). Both UK-PSC risk scores were well-validated in our external 
cohort and outperformed the Mayo Clinic and aspartate aminotransferase-to-platelet ratio index (APRI) scores 
(C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte 
antigen (HLA)-DR*03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addi-
tion did not improve the predictive accuracy of the UK-PSC risk scores. Conclusion: Our analyses, based on a 
detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of 
clinical risk markers and reports the development and validation of a real-world scoring system to identify those 
patients most likely to die or require liver transplantation. (Hepatology 2019;69:2120-2135).
Primary sclerosing cholangitis (PSC) is a chronic fibrosing cholestatic liver disease that is fre-quently associated with inflammatory bowel 
disease (IBD).(1) Disease progression culminates in 
end-stage liver disease and a high likelihood of death 
without liver transplantation.(2) Patients with PSC 
have up to a 15% lifetime risk of developing cholan-
giocarcinoma, which parallels their risk of colorectal 
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cancer.(1,3-5) Insights into disease pathogenesis are 
limited, but genetic studies highlight the importance 
of the adaptive immune system, with the strongest 
genetic association found within the human leukocyte 
antigen (HLA) locus.(6-8)
Clinical course is variable, and efforts to individ-
ualize risk prediction are important for patients, cli-
nicians, and trials of experimental agents.(9) Existing 
studies suggest that various clinical factors may pre-
dict the risk of adverse outcome. For example, ele-
vated immunoglobulin G (IgG) 4 concentration is 
reportedly associated (although not robustly validated) 
with an increased risk of progression to cirrhosis.(10,11) 
Conversely, small-duct PSC confers an improved sur-
vival and lower risk of cholangiocarcinoma,(12) as does 
a reduction in serum alkaline phosphatase (ALP) 1-2 
years following diagnosis.(13-15) Using cutoffs previously 
defined as stratifiers of risk in small bile duct disease 
primary biliary cholangitis (PBC), two studies have 
confirmed the independent prognostic value of ALP 
in PSC cohorts.(13,14) However, many studies evaluat-
ing risk prediction models in PSC have been limited 
by sample size, tertiary center recruitment bias, fail-
ure to control for the interaction of variables with one 
another, and lack of validation.(16) With the exception 
of the revised Mayo Clinic model (Mayo), previous 
prognostic models include histological staging.(17-21) 
Although it is not unexpected that histology is a pre-
dictor of outcome, as surrogates of liver fibrosis such as 
enhanced liver fibrosis score and transient elastography 
perform equally well(22,23), a simpler prognostic scoring 
is warranted. The revised Mayo Clinic model that was 
published in 2000 was designed to predict short-term 
survival within the proceeding 4 years and does not 
predict the need for transplantation.(21) Updated scor-
ing systems such as the Amsterdam-Oxford model are 
designed to predict PSC-related death and liver trans-
plant, but demonstrate only moderate predictive power 
(C statistic = 0.68), likely attributable to its limited 
study-cohort size.(24)
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Given our ability to capture the clinical charac-
teristics of a large, clinically representative cohort 
of patients with PSC through the UK National 
Institute for Health Research PSC (UK-PSC) Rare 
Disease Translational Research Cohort, we sought 
to describe the clinical course of PSC and to iden-
tify clinical and genetic features early in the dis-
ease course that are associated with increased risk 
of transplantation or death. In doing so, our sub-
sequent internationally validated findings provide 
clinically meaningful approaches to individualized 
risk prediction.
Materials and Methods
StUDy DeSIgN
Using data from patients recruited to the UK-PSC 
research cohort (www.uk-psc.com), we evaluated par-
ticipants with PSC who were at least 18 years of age 
with PSC incident or prevalent between August 1, 
2008, and March 31, 2015, including liver transplant 
recipients who had undergone transplantation for 
PSC at any point before March 31, 2015. Participants 
were recruited from throughout the United Kingdom 
across a research network of 155 collaborating 
National Health Service (NHS) Trusts, including 
nearly every hospital providing general or specialist 
hepatology services in the United Kingdom, excluding 
Northern Ireland.
Inclusion criteria were based on accepted diagnos-
tic criteria for PSC(25) and included the presence of 
cholestatic liver biochemistry tests with character-
istic bile duct changes on either endoscopic retro-
grade cholangio-pancreatography, magnetic resonance 
cholangio-pancreatography and/or liver histology. To 
address the challenges faced outside of clinical trials 
with comparing magnetic resonance images, the dis-
tinction between intrahepatic and extrahepatic bili-
ary disease was determined by a team review of local 
radiographic reports of cholangiographic imaging, 
as opposed to a single expert review. Involvement of 
first-order bile ducts (right or left main hepatic duct) 
and/or common bile duct at cholangiography were 
classified as extrahepatic biliary disease, as opposed 
to their absence being classified as intrahepatic biliary 
disease. Exclusion criteria included congenital abnor-
malities of the biliary tree, previous biliary surgery 
likely to cause secondary sclerosing cholangitis, pri-
mary bile duct carcinoma, human immunodeficiency 
virus cholangiopathy, PBC, positive antimitochondrial 
antibody, hepatic sarcoidosis, and drug-induced liver 
injury.
The study was conducted in accordance with the 
guidelines of the Declaration of Helsinki and the 
principles of good clinical practice. All participants 
provided written informed consent. Multiregional 
Ethics Committee approval was granted by the 
Cambridgeshire 4 National Ethics Committee (No. 
08/45/008) and by the research and development 
department of each collaborating hospital.
Data CaptURe
Data were collected using prespecified question-
naires through a systematic review of case notes 
between March 31, 2013, and March 31, 2015. Data 
included patient demographics, diagnostic cholan-
giography/histology reports, serial biochemistry at 
diagnosis (t0), 1-year following diagnosis (t1) and 
2-years following diagnosis (t2), IBD status, concom-
itant autoimmune disease, use of ursodeoxycholic acid 
(UDCA), development of malignancy or liver decom-
pensation, and progression to transplantation or death. 
Seventy-four percent of all data was collected by the 
lead clinician researcher (E.C.G.) during site visits 
to each hospital, and completed questionnaires were 
reviewed by a second clinician researcher for accuracy 
and missing data. The remaining 26% of data was col-
lected by the responsible clinician or research nurse 
at each hospital site, and reviewed by the lead clini-
cian researcher (E.C.G.) following return. In cases in 
which patients were under the care of more than one 
hospital (e.g., a transplant center and a general hos-
pital), the questionnaire was sent sequentially to each 
hospital to ensure complete data capture. Missing or 
inaccurate data were systematically queried with the 
clinician who had completed the questionnaire to 
ensure complete and accurate data capture. Data that 
passed quality control were uploaded into a bespoke 
secure database.
StUDy eNtRy aND oUtCoMe
We calculated the time from PSC diagnosis to 
outcome event. The value of t0 was defined as the 
date of first cholangiographic imaging or liver biopsy 
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demonstrating PSC. The first primary endpoint was 
liver transplantation, chosen as an important hard 
outcome for which a definitive time point is eas-
ily available. In the context of liver disease, it can 
be difficult to accurately define deaths solely related 
to liver disease; therefore, the second primary end-
point of all-cause mortality was chosen as the most 
encompassing term that would include all liver- 
related deaths. Participants who did not reach an 
endpoint were censored at the date of their most 
recent blood tests or follow-up. To be sure we cap-
tured all outcome events, we made use of the fact 
that every UK patient has a unique NHS number, 
which ensures that clinical coding is linked across 
primary, secondary, and tertiary care. This practice, 
in place throughout the 40-year study follow-up 
duration, ensures that the risk of missed events was 
minimal, and did not bias the analysis.
eXplaNatoRy VaRIaBleS
We considered variables for their association 
with outcome and inclusion in the risk score, based 
on clinical relevance or pre-existing evidence. To 
account for variability in the measurement of lab-
oratory investigations, alkaline phosphatase (ALP) 
was taken as a ratio of the upper limit of normal 
range (ULN) for the reporting laboratory. Other 
laboratory measures used the following standard 
units of measurement: hemoglobin (g/L), plate-
let count × 109/L, albumin (g/L), and bilirubin 
(μmol/L).
ClINICal Data aNalySIS
We calculated and reported descriptive statistics 
as numbers or percentages. Variables with more than 
40% missing data were excluded from further analy-
sis. For this reason, the following variables were omit-
ted from the analysis: international normalized ratio, 
aspartate aminotransferase (AST), IgG subclasses, 
and date of first hepatic decompensation (e.g., asci-
tes, hepatic encephalopathy, jaundice). Time-to-event 
analysis was conducted using Cox’s proportional haz-
ards model, ensuring at least 10 events per risk factor 
would be included in the model.(26) To facilitate accu-
rate risk prediction, events were truncated at 10 years 
of follow-up. To ensure sufficient variation within the 
data set, categorical variables were only considered if 
the categories had more than 5% of the cohort in each 
category. Variables that were present in less than 5% 
of the cohort, and thus excluded from the analysis, 
were smoking status and variceal hemorrhage at t0.
We performed unadjusted/univariate analysis on 
the raw data set to demonstrate associations between 
risk factors and outcome. To account for missing 
data, we performed multivariable imputation using 
iteratively chained equations, combined the results 
of 10 imputed data sets using Rubin’s equations, 
and estimated the adjusted/multivariable model 
using this imputed data set. We selected variables 
for the final risk score using backward elimination, 
with removal of risk factors not significant at the 
10% level.(27) Continuous variables were assessed for 
nonlinear association using cubic splines. Variables 
demonstrating a linear association were included in 
a standard, continuous fashion. Variables demon-
strating a nonlinear association were categorized 
using cubic splines and clinical judgment to allow 
for ease of interpretation.
alp
We analyzed the association between ALP at 
t1 and t2 with outcome, to determine the optimal 
threshold for predicting 10-year hazard of outcome. 
ALP was divided into categorical variables from less 
than or greater than or equal to 0.5 to 4 × ULN, 
in increments of 0.1. We plotted each ALP cutoff 
against the hazard of reaching an endpoint. The 
optimal threshold for ALP was determined using 
Harrell’s C statistic.
DeRIVatIoN oF tHe UK-pSC RISK 
SCoReS
We derived three separate risk scores to determine 
the model with the best discrimination. The first was a 
score using t0 data to predict 10-year risk of outcome, 
the second a short-term risk score using t0 data to 
predict 2-year risk of outcome (RSST), and the third, 
a long-term risk score using t0 and t2 data to predict 
10-year risk of outcome (RSLT). The RSLT included 
only those patients not reaching a primary endpoint 
within 2 years of diagnosis. The discrimination of 
each score was compared using Harrell’s C statistic. 
Calibration curves for RSST and RSLT were generated 
by creating deciles of data and comparing the model’s 
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predicted rates with the observed rates in the cohort, 
estimated by the Kaplan-Meier curve.
ValIDatIoN oF tHe UK-pSC RISK 
SCoReS
We used data from two external PSC patient 
cohorts that were not included in the original anal-
ysis, to validate the UK-PSC risk scores: the first a 
national validation cohort (n = 352) from two UK 
hospitals (Transplant Center at Queen Elizabeth 
Hospital Birmingham and John Radcliffe Hospital, 
Oxford [a nontransplant center])(24) and the second 
an international validation cohort from Norway 
(n = 99). Methods of validation cohort data collec-
tion were identical to the derivation cohort, and ret-
rospective data from individual auditing of electronic 
and paper case notes by clinician researchers were 
followed by quality control. Validation of the scoring 
system was performed by fitting a Cox model to the 
validation cohort using the scoring system derived 
from the derivation cohort.(28) Further visual vali-
dation was performed by displaying Kaplan-Meier 
survival curves for risk groups in both cohorts.(28) 
Risk groups were defined by dividing the derivation 
cohort into four equally sized groups with increas-
ing RSLT, and the validation cohort divided into 
four groups according to the same RSLT categories.
CoMpaRISoN oF tHe UK-pSC 
SCoRe WItH eXIStINg SCoReS
We analyzed the predictive ability of the modified 
Mayo risk score and AST-to-platelet ratio index 
(APRI) scores in both the derivation and valida-
tion cohorts, comparing them to the UK-PSC risk 
scores using Harrell’s C statistic. Both the Mayo and 
APRI score algorithms include AST. However, in 
most UK hospitals, AST is not measured as part of 
the standard liver biochemical tests; therefore, AST 
was not available for calculation of the Mayo risk 
or APRI scores. Other studies have demonstrated 
some equivalence of AST and ALT.(29) Using a sub-
set of patients for which both AST and ALT data 
were available at the same time points, we demon-
strated the correlation and concordance between the 
two variables. We then used ALT in place of AST 
in the calculation of the Mayo risk score and APRI 
scores.
geNetIC Data aNalySIS
Previous genotyping was conducted using the 
Illumina Immunochip,(7) a targeted genotyping array 
with dense marker coverage across 186 known disease 
loci from 12 immune-mediated diseases. We consid-
ered the following HLA risk alleles that are known 
to be associated with PSC disease risk from genome-
wide association studies(6,7): HLA-B*08:01 and HLA-
DRB1*03:01, 04:01, 07:01, 13:01, and 15:01. The 
association between HLA risk alleles and outcome as 
analyzed using a test for trend across zero, one, and 
two copies of each allele. We also tested for associ-
ation between significant risk alleles and important 
clinical variables. After applying a Bonferroni cor-
rection, our threshold for statistical significance was 
P < 0.008.
All analyses were performed using Stata software 
(version 14.0/SE; StataCorp, College Station, TX). 
This study was conducted and reported in accordance 
with TRIPOD (transparent reporting of a multi-
variate prediction model for individual prognosis or 
diagnosis).(30)
Results
CoHoRt CHaRaCteRIStICS
A total of 1,749 patients were recruited to the 
UK-PSC cohort; 1,252 questionnaires were distrib-
uted and 1,131 returned; 130 were excluded following 
quality control (Fig. 1), leaving 1,001 patients for anal-
ysis who were recruited from 108 hospitals, includ-
ing 7 transplant centers. Fifty-seven percent were 
recruited from non–transplant centers. The cohort 
(Table 1) included 64% males who were diagnosed at 
a median age of 46.8 years with median follow-up of 
14.8 years (range 0.2-40.4), censored at the time of 
transplant. Forty-four percent had extrahepatic bil-
iary disease and 72.5% had concomitant IBD, most 
commonly ulcerative colitis (80.4%), and 14.3% of the 
cohort had another autoimmune disease. UDCA was 
prescribed for 58% of the cohort within the first 2 
years following diagnosis.
A total of 35.7% of patients reached a primary 
endpoint over a cumulative follow-up period of 
7,904 years; 27.8% underwent liver transplan-
tation at a median age of 47.0 years; 7.9% died 
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without a transplant; and 47.8% of all deaths were 
PSC-related. The overall proportion of the cohort 
who were event-free at 2, 5, and 10 years was 
92%, 82% and 64%, respectively. Thirty-nine per-
cent of men reached an outcome, compared with 
29% of females (χ2 = 10.07, P = 0.002), and 43% 
of those with extrahepatic biliary disease reached 
an outcome compared with 23% of those without 
(χ2 = 40.6, P = 0.00). Patients with extrahepatic bil-
iary disease had a reduced median transplant-free 
survival compared with those without extrahepatic 
biliary disease (11.7 years versus 23 years). UDCA 
use in the first 2 years following diagnosis was 
not associated with outcome. Eleven percent of 
patients developed a gastrointestinal cancer, most 
commonly colorectal (5.4%), followed by cholan-
giocarcinoma (3.3%).
SeRUM alp IS aSSoCIateD WItH 
pSC oUtCoMe
ALP data at t1 and t2 were available for 72% and 
70% of the cohort, respectively. At both time points, 
elevated ALP was associated with an increased 10-year 
hazard of reaching an outcome (P ≤ 0.001) (Fig. 2A,B). 
There was a log-linear association between serum 
ALP and outcome; however, for ease of interpreta-
tion we chose to categorize ALP using cubic splines 
(Supporting Fig. S1). At t1, the optimal threshold for 
predicting 10-year outcome was ALP ≥ 2.4 × ULN 
(HR = 3.05, C = 0.63) (Fig. 2C), where median trans-
plant-free survival was 63 versus 108 months for those 
with ALP < 2.4 × ULN (P < 0.0001 [log-rank test]) 
(Fig. 2E). At t2, the optimal threshold for predicting 
10-year outcome was ALP ≥ 2.2 × ULN (HR = 3.05, 
FIg. 1. Study f low diagram.
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C = 0.66) (Fig. 2D), where median survival was 44 
versus more than 96 months for those with a t2 ALP 
< 2.2 × ULN (P < 0.0001 [log-rank test]) (Fig. 2F).
DISeaSe DIStRIBUtIoN IS 
aSSoCIateD WItH oUtCoMe IN 
pSC
Cholangiographic data at t0 were available in 87.2% 
of the cohort. Presence of extrahepatic biliary disease 
was associated with adverse outcome (HR = 1.45 (con-
fidence interval [CI] 1.09, 1.92), P = 0.010). Patients 
without extrahepatic biliary disease had improved 
10-year event-free survival, although more than 50% 
of both groups were event-free at 10 years; thus, the 
median survival was not reached (Supporting Fig. S2).
DeRIVatIoN oF tHe UK-pSC RISK 
SCoReS
Our first UK-PSC risk score used variables 
available at t0 to predict 10-year risk of outcome. 
Following multivariable analysis, seven factors were 
included in the score: age at t0, bilirubin, ALP, albu-
min, hemoglobin, platelets, and presence of extra-
hepatic biliary disease a t0 (Supporting Table S1) 
(C = 0.78, shrinkage = 0.94). Our cohort demon-
strated a high event rate (8%) within the first 2 
years of diagnosis. Therefore, to determine whether 
variables predicting short-term and long-term risk 
differed, we derived a short-term risk score (RSST) 
using variables at t0 to predict the risk of outcome 
within 2 years following diagnosis, and a long-term 
taBle 1. Demographics of the UK-pSC Derivation Cohort (n = 1,001), National Validation Cohort (n = 352), and 
International Validation Cohort (n = 99)
Variable
Derivation Cohort Validation Cohorts
n = 1,001 (%) National n = 352 (%) International n = 99 (%)
Demographics Male 63.8 62.4 75.7
Mean age at diagnosis (years) 46.8 45.0 35.0
Median age at transplant 47 47.0 39.0
Median follow-up (years) 14.8 6.0 8.0
Disease distribution Extrahepatic biliary disease present 44.1 47.8 33.3
IBD IBD 72.5 71.0 86.0
Ulcerative colitis 80.4 73.6 77.6
Crohn’s colitis 14.2 10.7 15.3
Indeterminate colitis 5.4 3.2 7.1
Autoimmune disease Autoimmune disease 14.3 — —
Thyroid disease 6.9 — —
Rheumatoid arthritis 2.3 — —
Celiac disease 2.0 — —
Other 6.2 — —
Smoking status Never smoked 53.2 — —
Ex-smoker 26.5 — —
Current smoker 3.7 — —
Events Total events 35.7 39.2 32.3
Transplants 27.8 13.9 11.1
Deaths (all causes) 7.9 25.3 21.2
Cancers Gastrointestinal cancer 10.7 — —
Colorectal 5.4 — —
Cholangiocarcinoma 3.3 — —
Gall bladder 1.3 — —
Hepatocellular carcinoma 0.6 — —
Pancreatic 0.1 — —
UDCA use Taking UDCA at year 2 57.8 — —
Median dose (mg/kg) 11.4 — —
Range (mg/kg) 2.2-46.8 — —
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risk score (RSLT) using variables from t2 to predict 
10-year risk of outcome (see Box). Mean serum 
ALT, platelet count, and ALP ratio were all signifi-
cantly reduced from t0 to t2 (Supporting Table S2). 
Both RSST and RSLT demonstrated improved pre-
dictive ability over the original model.
Short-term UK-pSC Risk Score (RSSt)
Four variables at t0 were associated with 2-year 
outcome: bilirubin, albumin, hemoglobin, and plate-
let count (Table 2). Based on these coefficients, a 
prognostic model was developed to predict the risk 
of death or liver transplantation by year 2 (C = 0.81, 
shrinkage = 0.92) (Box 1).
long-term UK-pSC Risk Score (RSlt)
Seven variables at t2 were associated with 10-year 
risk of outcome: age at diagnosis, bilirubin at t2, ALP 
at t2, albumin at t2, platelets at t2, presence of extra-
hepatic biliary disease at t0, and variceal hemorrhage 
by t2 (C = 0.80, shrinkage = 0.96) (Table 3 and Box 
1). Calibration of RSST and RSLT using predicted ver-
sus observed survival rates estimated by Kaplan-Meier 
curve demonstrated good correlation. The scores are 
available at http://www.uk-psc.com/riskscores.
To define low-risk and high-risk disease groups 
according to RSLT, we divided the derivation cohort 
into four equal quartiles. Event-free survival, plotted 
on a Kaplan-Meir survival curve (Fig. 3A), demon-
strated observed event rates of 6.0%, 8.4%, 19.1%, 
and 55.8% in the four respective risk groups. Curves 
were generally well separated, although the model was 
less able to distinguish between the two lowest risk 
groups. The value of RSLT, which defines the four risk 
groups, is provided in Supporting Table S3.
ValIDatIoN oF tHe UK-pSC 
SCoReS
We analyzed the predictive ability of both risk 
scores in a separate national and international patient 
cohort. In the respective national and international 
validation cohorts (Table 1), 62.4% and 75.7% of the 
cohort were male, diagnosed at a median age of 47 
and 39 years, with 71% and 86% diagnosed with con-
comitant IBD. The most notable differences between 
the derivation and validation cohorts were the shorter 
BoX 1
Short-term UK-pSC Risk Score (RSt) = 0.745(Bili_t0 
Group 1 [0/1] + 1.613(Bili_t0 Group 2 [0/1]) – 0.061(Alb_t0 
[g/l]) – 0.012(Hb_t0 [g/l]) – 0.476(Plts_t0 Group 1 [0/1]) – 
0.698(Plts_t0 Group 2 [0/1]) – 0.962(Plts_t0 Group 3 [0/1]).
long-term UK-pSC Risk Score (RSlt) = 0.026(Age_
t0[yrs]) + 1.197(Bili_t2 Group 1 [0/1]) + 1.38(Bili_t2 Group 
2 [0/1]) + 0.4(ALP_t2 Group 1 [0/1]) + 0.45(ALP_t2 Group 
2 [0/1]) –0.07(Alb_t2[g/l]) –0.543(Plts_t2 Group 1) – 
0.503(Plts_t2 group 2) – 0.768(Plts_t2 Group 3 [0/1]) + 
0.524(disease type_t0 [0/1]) + 1.014(variceal bleed_t2 [0/1]).
Bili_t0/t2 group 1: 0 = Bili_t0 < 35 μmol/L or > 50 μmol/L, 1 = 
35 to ≤ 50 μmol/L
Bili_t0/t2 group 2: 0 = Bili_t0 < 50 μmol/L, 1 = Bili_t0 ≥ 50 
μmol/L
Plts_t0/t2 group 1: 0 = Plts_t0 < 150 × 109/L, or ≥ 200 × 109/L, 
1 = Plts_t0 150 to < 200 × 109/L
Plts t0/t2 group 2: 0 = < 200 or ≥ 400 × 109/L, 1 = 200 to < 400 
× 109/L
Plts_t0/t2 group 3: 0 = < 400 × 109/L, 1 = ≥ 400 × 109/L
ALP_t2 group 1: 0 = ALP_t2 < 1.5 × ULN or ≥ 2.5 × ULN, 1 = 
1.5 to < 2.5
ALP_t2 group 2: 0 = ALP_t2 < 2.5 × ULN, 1 = ≥ 2.5 × ULN
Disease type_t0: 0 = no extrahepatic biliary disease; 1 = presence 
of extrahepatic biliary disease
Variceal bleed_t2: 0 = no bleed by t2; 1 = bleed by t2
predicted survival rate at time t: (baseline survival at time t) 
^ exp (RSST or RSLT)
RSSt baseline survival at time t: 1 year: 0.0096612; 2 years: 
0.0001109
RSlt baseline survival at time t: 1 year: 0.9218476; 2 years: 
0.8227174; 5 years: 0.7070919; 8 years: 0.2771266
example
An individual aged 47 and with no evidence of extrahepatic 
disease at diagnosis presented with the following biochemis-
try at t0: bilirubin 37 μmol/L, albumin 34 g/L, hemoglobin 
130 g/L, and platelets 245 × 109/L; and the following bio-
chemistry at t2: bilirubin 24 μmol/L, ALP 2 × ULN, albu-
min 30 g/L, platelets 152 × 109/L, and no variceal bleed by 
t2. This would score RSST = (0.745 × 1) – (0.061 × 34) – 
(0.012 × 130) – (0.698 × 1) = –3.587. Predicted event-free 
survival rate at 2 years = (0.0001109)^exp (–3.587) = 0.78 = 
78%. Long-term risk score would be RSLT = (0.026 × 47) + 
0.403 + (–0.07 × 30) – 0.543 = –1.018. Predicted event-free 
survival rate at 5 years = 0.707^exp (–1.047) = 0.885 = 88.5%.
the UK-pSC risk scores are available at http://www.uk-
psc.com/riskscores.
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median follow-up (6 years and 8 years in the national 
and international cohorts, versus 14.8 years), higher 
death rate (25.3% and 21.2% versus 7.9%), and lower 
transplant rate (13.9% and 11.1% versus 27.8%).
Both the RSST and RSLT were associated with out-
come in the national validation cohort (P < 0.001). 
The slope of the Cox model for the RSST in the val-
idation cohort was 1.09, which is not significantly 
FIg. 2. Predictive value of ALP and outcome. (A) Association between ALP (as ratio of ULN) at year 1 and hazard of reaching a 
clinical endpoint within 10 years, with 95% CI. (B) Association between ALP (as ratio of ULN) at year 2 and hazard of reaching a 
clinical endpoint within 10 years, with 95% CI. (C) Harrell’s C statistic per ALP cutoff point at year 1 for 10-year hazard of outcome. 
(D) Harrell’s C statistic per ALP cutoff point at year 2 for 10-year hazard of outcome. (E) Kaplan-Meier survival curve for transplant-
free survival in patients with ALP  2.4 × ULN (blue line) versus ALP > 2.4 × ULN (red line) at 1 year following diagnosis (0 = 12 
months after diagnosis). (F) Kaplan-Meier survival curve for transplant-free survival in patients with ALP  2.2 × ULN (blue line) versus 
ALP > 2.2 × ULN (red line) at 2 years following diagnosis (0 = 24 months after diagnosis).
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different from 1, indicating that the discrimination 
was preserved. The slope for the RSLT was 1.36 
(P = 0.0071), which is significantly different from 1, 
suggesting that the score is more predictive of out-
come in the validation than the derivation cohort. In 
the international validation cohort, the lack of events 
within the first 2 years meant that only the RSLT could 
be validated. The RSLT was associated with outcome 
in the international validation cohort (P < 0.001): The 
slope was 1.60 and not significantly different from 
1 (P = 0.014), indicating preserved discrimination, 
although this was based on only 37 individuals.
Further visual validation of the RSLT was performed 
by comparing Kaplan-Meier survival curves for the val-
idation cohort according to the same four previously 
defined risk groups as the derivation cohort (Fig. 3A,B). 
Event rates were similar to the derivation cohort at 2.9%, 
10.4%, 20.0%, and 47.9% (Supporting Table S3). Both 
sets of four curves were quite well separated, confirming 
that the model had discrimination in both cohorts; how-
ever, the model was less able to distinguish between the 
two intermediate risk groups in the validation cohort.
CoMpaRISoN oF UK-pSC SCoRe 
WItH eXIStINg SCoReS
We compared the predictive accuracy of the Mayo 
and APRI scores to the RSST and RSLT in the imputed 
derivation data set. Based on a subset of 170 patients 
from the validation cohort, for which both AST and 
ALT measurement were available for t0 and t2, there 
was a strong correlation (r = 0.94, P < 0.0001) and 
taBle 2. Univariate analysis Using Unimputed Data, and Multivariate analysis Using Imputed Data, of Factors at Diagnosis 
associated With 2-year Risk of transplantation or Death
Factor
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HHR (95% CI) P Value
Female 0.88 (0.54, 1.42) 0.596
Age at diagnosis 1.01 (1.00, 1.03) 0.126
Extrahepatic biliary disease 1.30 (0.77, 2.21) 0.332
IBD presence 1.09 (0.49, 2.44) 0.832
Ulcerative colitis 1.12 (0.67, 1.89) 0.665
Crohn’s disease 0.39 (0.12, 1.31) 0.127
Indeterminate colitis 1.38 (0.47, 4.03) 0.560
Autoimmune disease 0.90 (0.46, 1.75) 0.757
Smoker 1.22 (0.74, 2.02) 0.426
Bilirubin (μmol/L)
35-49 4.03 (1.36, 11.98) 0.012 2.11 (0.74, 5.96) 0.159
50+ 14.12 (7.89, 25.3) < 0.001 5.02 (2.76, 9.13) < 0.001
ALP (ratio of ULN)
1.5 to < 2.5 1.25 (0.49, 3.17) 0.634
2.5+ 2.64 (1.35, 5.17) 0.005
ALT (IU/L)* 1.02 (0.98, 1.05) 0.331
Albumin (g/L) 0.87 (0.84, 0.90) < 0.001 0.94 (0.90, 0.99) 0.011
Hemoglobin (g/L)† 0.98 (0.97, 0.99) < 0.001 0.99 (0.97, 1.00) 0.095
Platelets group (×109/L)
150-199 0.23 (0.08, 0.72) 0.011 0.62 (0.26, 1.48) 0.283
200-399 0.22 (0.11, 0.45) < 0.001 0.50 (0.25, 0.98) 0.045
400+ 0.32 (0.13, 0.78) 0.012 0.38 (0.15, 0.98) 0.046
Eosinophils (×109/L) 1.10 (0.89, 1.36) 0.368
Sodium (mmol/L) 0.89 (0.82, 0.98) 0.015
Creatinine > 120 (µmol/L) 4.21 (1.66, 10.68) 0.002
IgG (g/L)* 1.08 (0.93, 1.25) 0.313
*Denotes HR for a 10-unit change.
†Denotes HR for a 1-unit change.
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strong concordance (C = 0.92, P < 0.0001) between 
the two variables. ALT was therefore used in place of 
AST for calculation of the Mayo and APRI scores. In 
predicting 2-year outcome, the RSST out-performed 
the APRI and Mayo scores with C statistics of 0.81, 
0.63, and 0.75, respectively. In predicting 10-year 
outcome the RSLT demonstrated an incremental 
improvement over the APRI and Mayo scores with C 
statistics of 0.80, 0.59, and 0.79, respectively.
We then compared the predictive accuracy of the 
Mayo and Model for End-Stage Liver Disease (MELD) 
scores to the RSST and RSLT in the validation data set. 
In predicting 2-year outcome, the RSST out-performed 
the Mayo and MELD scores with C statistics of 0.81, 
0.73, and 0.78, respectively. In predicting 10-year 
outcome, the RSLT demonstrated a markedly improved 
predictive accuracy compared with Mayo and MELD, 
with C statistics of 0.85, 0.69, and 0.70, respectively.
Hla RISK alleleS aRe 
aSSoCIateD WItH oUtCoMe
THE HLA genotype was available for 635 
patients. Twenty-seven percent and 9% of the 
cohort were heterozygous and homozygous for the 
HLA-DR*03:01 risk allele, respectively. Presence of 
this allele was associated with outcome in a dose-de-
pendent manner (HR = 1.33, CI 1.13, 1.58, P = 0.001) 
(Supporting Table S4). After testing for association 
between HLA-DR*03:01 and clinical characteristics 
taBle 3. Univariate analysis Using UnImputed Data, and Multivariate analysis Using Imputed Data, of Factors at year 2 
associated With 10-year Risk of transplantation or Death
Factor
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HHR (95% CI) P Value
Female 0.81 (0.60, 1.10) 0.181
Age at diagnosis 1.01 (1.00, 1.03) 0.005 1.03 (1.01, 1.04) < 0.001
Extrahepatic biliary disease 1.95 (1.42, 2.69) < 0.001 1.70 (1.15, 2.48) 0.008
IBD 0.91 (0.59, 1.38) 0.646
Ulcerative colitis 0.92 (0.70, 1.22) 0.558
Crohn’s disease 0.68 (0.41, 1.11) 0.122
Indeterminate colitis 1.28 (0.71, 2.31) 0.416
Autoimmune disease 1.27 (0.88, 1.83) 0.200
Smoker 0.96 (0.70, 1.32) 0.790
Bilirubin (μmol/L)
35-49 6.77 (3.87, 11.85) < 0.001 3.31 (1.65, 6.62) 0.001
50+ 7.92 (5.62, 11.18) < 0.001 3.96 (2.37, 6.62) < 0.001
ALP (ratio of ULN)
1.5-2.4 1.75 (0.98, 3.15) 0.061 1.50 (1.09, 2.30) 0.015
2.5+ 1.40 (1.04, 1.88) 0.025 1.57 (1.12, 2.52) 0.011
ALT (IU/L)* 1.05 (1.03, 1.08) < 0.001
Albumin (g/L) 0.88 (0.85, 0.90) < 0.001 0.93 (0.90, 0.96) < 0.001
Hemoglobin (g/L)* 0.75 (0.69, 0.81) < 0.001
Platelets group (×109/L)
150-199 0.35 (0.20, 0.60) < 0.001 0.58 (0.31, 1.10) 0.092
200-399 0.29 (0.20, 0.43) < 0.001 0.60 (0.40, 0.91) 0.016
400+ 0.32 (0.17, 0.60) < 0.001 0.46 (0.23, 0.92) 0.028
Eosinophils (×109/L) 0.81 (0.52, 1.29) 0.380
Sodium (mmol/L) 0.90 (0.96, 0.93) < 0.001
Creatinine > 120 (µmol/L) 0.66 (0.21, 2.07) 0.474
IgG (g/L)* 1.01 (0.92, 1.12) 0.774
UDCA use 0.96 (0.72, 1.28) 0.795
Variceal bleed by year 2 5.97 (2.93, 12.16) < 0.001 2.76 (1.14, 6.66) 0.024
*Denotes HR for a 10-unit change.
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at diagnosis, we found HLA-DR*03:01 risk alleles to 
be inversely correlated with mean age at diagnosis (no 
copies = 47.6 years, heterozygote = 46.6 years, homo-
zygote = 40.8 years, P = 0.007) (Supporting Table S5). 
The addition of the HLA-DR*03:01 risk allele to the 
risk score did not improve the discrimination of the 
model. No association was observed with HLA-B*08, 
HLA-DR*04:01, 07:01, 13:01, or 15:01.
Discussion
Using a large cohort of 1,001 patients from across 
the entire United Kingdom, including 57% recruited 
from non–transplant centers, representing the full 
spectrum of PSC disease severity, we provide import-
ant, externally validated clinical and genetic modeling 
based on readily available clinical factors for prediction 
FIg. 3. Kaplan-Meir survival curves for four risk groups. Risk group 1: RSLT > −2.019879 (blue line); risk group 2: −1.463874 < RSLT  
< −2.019879 (red line); risk group 3: −0.8146346 < RSLT < −1.463874 (green line); risk group 4: 2.737384 < RSLT < −0.8146346 (orange 
line). (A) Derivation cohort Kaplan-Meir survival curves for four risk groups. (B) Validation cohort Kaplan-Meir survival curves for 
four risk groups.
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of short-term and long-term outcome. Based on the 
presence of extrahepatic biliary disease at t0, age, bil-
irubin, ALP, albumin and platelets at t2, and variceal 
hemorrhage by t2, we present a scoring system that 
has value both in individual risk evaluation as well as 
in being a potential mechanism to stratify recruitment 
to clinical trials.
Our study confirms the importance of ALP as a 
prognostic indicator, both individually and as part of 
our RSLT. We demonstrate that ALP < 2.4 × ULN 
and < 2.2 × ULN at 1 and 2 years following diag-
nosis respectively, is associated with improved trans-
plant-free survival. Understanding the behavior of 
ALP as a biomarker in PSC is of interest, and par-
allels interest in PBC. In PBC, dichotomous risk 
scores have C statistics of approximately 0.6, with 
the dynamic scores reporting C statistics of 0.8 and 
above.(31,32) Although in PSC, the serum ALP was 
not associated with short-term outcome, the prognos-
tic importance as a longer-term predictor of clinical 
events is highlighted by its inclusion in our long-term 
risk score. This may be explained by fluctuations in 
ALP in the early stages of diagnosis, which limit its 
prognostic value, and the rationale that short-term 
risk is driven by factors that measure cholestasis and 
portal hypertension. Thus, when considering ALP 
in isolation, we chose to consider ALP at t1 and t2 
rather than t0, and used this to predict long-term risk 
rather than short-term risk. In addition, our study 
demonstrated the poor prognostic effect of extrahe-
patic biliary disease, highlighting the importance of 
further study into cholangiographic monitoring in 
PSC. Although simple cholangiographic imaging 
used at diagnosis does carry meaningful prognostic 
data, improving cholangiographic evaluation remains 
important.
We observed a high event rate (8%) within the 
first 2 years following diagnosis, suggesting that 
there is a patient cohort who present late in disease 
course, or who experience rapidly progressive dis-
ease. Recognizing this, we developed separate risk 
scores for short-term (RSST) and long-term (RSLT) 
prediction, the key differences between them being 
that the former includes only laboratory parameters 
(bilirubin, albumin, hemoglobin, and platelets), sug-
gesting that intrinsic liver function is most import-
ant in predicting immediate outcome. Conversely the 
RSLT includes laboratory factors (bilirubin, albumin, 
platelets, and ALP) in addition to variceal bleeding 
and cholangiographic disease distribution. By using 
a dichotomous approach to risk stratification, we 
improved the predictive utility from C = 0.78 with 
our original score to C = 0.80 and 0.81 for short-
term prediction, and C = 0.80 and 0.85 for long-term 
prediction, in the derivation and validation cohorts, 
respectively. In practice, this would allow clinicians 
to recalculate risk at 2 years following diagnosis for 
greater prognostic accuracy.
There remains a risk of better performance of 
our model, due to data fitting; this is a risk that we 
acknowledge. We tried to address this by compar-
ing our risk scores versus existing scores, including 
the Mayo score. Although we reconfirm the Mayo 
risk score’s prognostic value, it was out-performed by 
our RSST and RSLT, which also confer several other 
advantages. Even though the Mayo score is based on 
the parameters of age, bilirubin, AST, variceal bleed-
ing and albumin, the UK-PSC risk scores consider 
more aspects of disease progression, including age, 
ALP, albumin, platelets, extrahepatic biliary disease, 
and variceal hemorrhage. The Mayo risk score pre-
dicts only 4-year risk of all-cause mortality and does 
not provide a strong long-term predictor of outcome. 
It performs best in patients with end-stage liver dis-
ease and does not consider the important outcome of 
liver transplantation. In comparison, the dichotomous 
UK-PSC risk scores predict short-term (2-year) and 
long-term (10-year) outcomes, ensuring that the pre-
dictive ability is as good for those patients presenting 
with early-stage, as well as late-stage, liver disease, and 
includes the important outcome of liver transplanta-
tion in addition to all-cause mortality.
We found that HLA-DR*03:01, a previously vali-
dated HLA risk allele, was an important predictor of 
disease outcome, demonstrating a gene-dose effect; 
however, the addition of HLA-DR*03:01 did not 
improve the predictive ability of our prognostic score. 
When considering effect size, HLA-DR*03:01 had 
an adjusted HR of 1.33 (CI 1.13, 1.58, P = 0.001) 
for outcome, which is more comparable to that of 
extrahepatic biliary disease or ALP, in comparison 
to the strongest associated clinical variable, bilirubin, 
which had an adjusted odds ratio of 3.96 (CI 2.4, 6.9, 
P < 0.001).
A strength of our cohort is the representative 
nature of the participants, notably identifying low-
risk as well as high-risk patients. In our study, we 
could define a “low-risk” disease group (patients with 
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a RSLT of ≤ 2.02 had a less than 10% chance of an 
event by their 10-year follow-up) and a “high-risk” 
group (patients with RSLT −0.81 < RSLT < 2.74 had 
an approximate 50% chance of an event by 10 years). 
Both UK-PSC risk scores (http://www.uk-psc.com/
riskscores) were well validated in a separate patient 
cohort. The major differences between the derivation 
and validation cohorts were a lower death and higher 
transplant rate in the former. There are some biases in 
our derivation cohort, reflective of ascertainment pro-
cesses. Recruitment to the UK-PSC derivation cohort 
was retrospective through prevalent case ascertain-
ment. Recruitment was therefore inherently biased 
toward those patients with or without transplant, 
who survived to 2008 to be recruited to the study, 
compared with those patients who died before 2008. 
Furthermore, there was a low prevalence of cholangio-
carcinoma (3.3%) in our cohort. Retrospective cohort 
recruitment is not well-suited to capturing data on 
outcome markers associated with very poor survival; 
nearly 50% of all PSC-associated cholangiocarci-
nomas manifest within 2 years of PSC diagnosis.(2) 
Despite these limitations, the UK-PSC risk scores 
were nationally and internationally well-validated in 
two external cohorts, lending weight to their impor-
tance as robust prognostic models.
Retrospective data collection also carries the inher-
ent drawback of incomplete data collection. Not sur-
prisingly, rates of missing data were higher for patients 
diagnosed many years previously. Given that it was 
only related to the year of diagnosis, we considered 
these data to be missing at random, and used impu-
tation to improve the validity of the results. Although 
a date of diagnosis before 1990 was associated with 
an improved transplant-free survival, removal of these 
patients from the analysis did not alter the strength 
of the reported associations with either short-term or 
long-term outcome; thus, they were retained for the 
purpose of statistical power.
In our study, we did not observe any differences 
in outcome according to sex or subtype of IBD. The 
evidence for female sex and Crohn’s disease confer-
ring a favorable outcome in patients with PSC has 
only been robustly supported by evidence from one 
large study that included more than 7,000 patients 
with PSC.(2) It is therefore likely that with a total 
sample size of 1,452, our study was underpowered to 
detect any such effect. Further studies of even larger 
cohorts, adjusted for multiple factors, are needed 
to confidently validate this finding. In particular, 
this necessitates careful, consistent classification of 
PSC-associated IBD.
We chose the endpoints of all-cause mortal-
ity and liver transplantation rather than hepatic 
decompensation (e.g., ascites, hepatic encephalop-
athy), because they provide a definitive and easily 
identifiable event and time of event that are nec-
essary for a retrospective observational study. In 
comparison, hepatic decompensation can remain 
undiagnosed for several months and the precise 
date of diagnosis remains subjective; such issues are 
less relevant in well-designed clinical trial/prospec-
tive cohort settings in which such endpoints are 
clearly meaningful and can be collected robustly. 
Arguably, there are challenges with our chosen 
endpoints due to possible variation in clinical prac-
tice and outcomes over time. Indeed, it must be 
acknowledged that changes in disease course over 
the time period of a study is a potential confound-
ing factor. Evaluating such changes can be hard: For 
example, contemporaneous reference literature may 
not reflect clinical changes to a disease manifesta-
tion, but report and investigate changes in clinical 
practices. Despite PSC being infrequent overall, 
and the difficulty in recruiting large cohorts for the 
development of well-powered evaluations, we have 
collated a unique data set that captures approxi-
mately 15% of the total UK PSC population, with 
substantial power to evaluate all-cause mortality 
and transplantation. Although accepting limitations 
inherent to our approach, there is no evidence to 
date that PSC outcomes have varied over the time 
course of our study, simply on the basis of era, and 
recent data reporting liver transplant practice in 
the United Kingdom additionally supports this.(33) 
Our approach is of significance to clinicians, as 
the risk score analyses best reflect collective real-
world clinical practice, with a focus on a spectrum 
of patients reflective of the disease. Moreover, the 
study was designed so that, through a large cohort 
size, it could accommodate the weaknesses intro-
duced by non-trial-based uniform evaluation and 
data capture.
In conclusion, our analyses, which are based on a 
detailed clinical evaluation of a large representative 
cohort of participants with PSC, have furthered our 
understanding of clinical risk markers for predicting 
outcome in patients with PSC.
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